T1	Participants 274 292	sixty-two patients
T2	Participants 555 820	62 patients were randomly assigned to receive either prednisone plus cyclophosphamide (intravenous bolus) (group A; n = 28) or prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges (group B; n = 34) as first-line treatment for severe PAN or CSS
T3	Participants 348 414	severe polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS)
